These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33562844)

  • 21. Ocular manifestations in Wolf-Hirschhorn syndrome.
    Dickmann A; Parrilla R; Salerni A; Savino G; Vasta I; Zollino M; Petroni S; Zampino G
    J AAPOS; 2009 Jun; 13(3):264-7. PubMed ID: 19541266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural analysis of pathogenic mutations in the DYRK1A gene in patients with developmental disorders.
    Evers JM; Laskowski RA; Bertolli M; Clayton-Smith J; Deshpande C; Eason J; Elmslie F; Flinter F; Gardiner C; Hurst JA; Kingston H; Kini U; Lampe AK; Lim D; Male A; Naik S; Parker MJ; Price S; Robert L; Sarkar A; Straub V; Woods G; Thornton JM; ; Wright CF
    Hum Mol Genet; 2017 Feb; 26(3):519-526. PubMed ID: 28053047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrative approach to interpret DYRK1A variants, leading to a frequent neurodevelopmental disorder.
    Courraud J; Chater-Diehl E; Durand B; Vincent M; Del Mar Muniz Moreno M; Boujelbene I; Drouot N; Genschik L; Schaefer E; Nizon M; Gerard B; Abramowicz M; Cogné B; Bronicki L; Burglen L; Barth M; Charles P; Colin E; Coubes C; David A; Delobel B; Demurger F; Passemard S; Denommé AS; Faivre L; Feger C; Fradin M; Francannet C; Genevieve D; Goldenberg A; Guerrot AM; Isidor B; Johannesen KM; Keren B; Kibæk M; Kuentz P; Mathieu-Dramard M; Demeer B; Metreau J; Steensbjerre Møller R; Moutton S; Pasquier L; Pilekær Sørensen K; Perrin L; Renaud M; Saugier P; Rio M; Svane J; Thevenon J; Tran Mau Them F; Tronhjem CE; Vitobello A; Layet V; Auvin S; Khachnaoui K; Birling MC; Drunat S; Bayat A; Dubourg C; El Chehadeh S; Fagerberg C; Mignot C; Guipponi M; Bienvenu T; Herault Y; Thompson J; Willems M; Mandel JL; Weksberg R; Piton A
    Genet Med; 2021 Nov; 23(11):2150-2159. PubMed ID: 34345024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DYRK1A-haploinsufficiency in mice causes autistic-like features and febrile seizures.
    Raveau M; Shimohata A; Amano K; Miyamoto H; Yamakawa K
    Neurobiol Dis; 2018 Feb; 110():180-191. PubMed ID: 29223763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome.
    Quiñones-Lombraña A; Blanco JG
    Exp Mol Pathol; 2019 Oct; 110():104268. PubMed ID: 31201803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
    Dowjat WK; Adayev T; Kuchna I; Nowicki K; Palminiello S; Hwang YW; Wegiel J
    Neurosci Lett; 2007 Feb; 413(1):77-81. PubMed ID: 17145134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DYRK1A: a potential drug target for multiple Down syndrome neuropathologies.
    Becker W; Soppa U; Tejedor FJ
    CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):26-33. PubMed ID: 24152332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired macroglial development and axonal conductivity contributes to the neuropathology of DYRK1A-related intellectual disability syndrome.
    Pijuan I; Balducci E; Soto-Sánchez C; Fernández E; Barallobre MJ; Arbonés ML
    Sci Rep; 2022 Nov; 12(1):19912. PubMed ID: 36402907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome.
    Wegiel J; Kaczmarski W; Barua M; Kuchna I; Nowicki K; Wang KC; Wegiel J; Yang SM; Frackowiak J; Mazur-Kolecka B; Silverman WP; Reisberg B; Monteiro I; de Leon M; Wisniewski T; Dalton A; Lai F; Hwang YW; Adayev T; Liu F; Iqbal K; Iqbal IG; Gong CX
    J Neuropathol Exp Neurol; 2011 Jan; 70(1):36-50. PubMed ID: 21157379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
    Wegiel J; Dowjat K; Kaczmarski W; Kuchna I; Nowicki K; Frackowiak J; Mazur Kolecka B; Wegiel J; Silverman WP; Reisberg B; Deleon M; Wisniewski T; Gong CX; Liu F; Adayev T; Chen-Hwang MC; Hwang YW
    Acta Neuropathol; 2008 Oct; 116(4):391-407. PubMed ID: 18696092
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel inhibitor rescues cerebellar defects in a zebrafish model of Down syndrome-associated kinase Dyrk1A overexpression.
    Buchberger A; Schepergerdes L; Flaßhoff M; Kunick C; Köster RW
    J Biol Chem; 2021 Jul; 297(1):100853. PubMed ID: 34090874
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Atas-Ozcan H; Brault V; Duchon A; Herault Y
    Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restrained Phosphatidylcholine Synthesis in a Cellular Model of Down's Syndrome is Associated with the Overexpression of Dyrk1A.
    Hijazi M; Medina JM; Velasco A
    Mol Neurobiol; 2017 Mar; 54(2):1092-1100. PubMed ID: 26803494
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dyrk1a Mutations Cause Undergrowth of Cortical Pyramidal Neurons via Dysregulated Growth Factor Signaling.
    Levy JA; LaFlamme CW; Tsaprailis G; Crynen G; Page DT
    Biol Psychiatry; 2021 Sep; 90(5):295-306. PubMed ID: 33840455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of Dyrk1A causes the defects in synaptic vesicle endocytosis.
    Kim Y; Park J; Song WJ; Chang S
    Neurosignals; 2010; 18(3):164-72. PubMed ID: 21135538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development.
    Dang T; Duan WY; Yu B; Tong DL; Cheng C; Zhang YF; Wu W; Ye K; Zhang WX; Wu M; Wu BB; An Y; Qiu ZL; Wu BL
    Mol Psychiatry; 2018 Mar; 23(3):747-758. PubMed ID: 28167836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration.
    Branchi I; Bichler Z; Minghetti L; Delabar JM; Malchiodi-Albedi F; Gonzalez MC; Chettouh Z; Nicolini A; Chabert C; Smith DJ; Rubin EM; Migliore-Samour D; Alleva E
    J Neuropathol Exp Neurol; 2004 May; 63(5):429-40. PubMed ID: 15198122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
    Kimura R; Kamino K; Yamamoto M; Nuripa A; Kida T; Kazui H; Hashimoto R; Tanaka T; Kudo T; Yamagata H; Tabara Y; Miki T; Akatsu H; Kosaka K; Funakoshi E; Nishitomi K; Sakaguchi G; Kato A; Hattori H; Uema T; Takeda M
    Hum Mol Genet; 2007 Jan; 16(1):15-23. PubMed ID: 17135279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.
    García-Cerro S; Vidal V; Lantigua S; Berciano MT; Lafarga M; Ramos-Cabrer P; Padro D; Rueda N; Martínez-Cué C
    Neurobiol Dis; 2018 Feb; 110():206-217. PubMed ID: 29221819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome.
    Arranz J; Balducci E; Arató K; Sánchez-Elexpuru G; Najas S; Parras A; Rebollo E; Pijuan I; Erb I; Verde G; Sahun I; Barallobre MJ; Lucas JJ; Sánchez MP; de la Luna S; Arbonés ML
    Neurobiol Dis; 2019 Jul; 127():210-222. PubMed ID: 30831192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.